Europe Inhaled Nitric Oxide Market Size, Share, Growth, 2026

Europe Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Country, Industry Analysis and Forecast, 2020 - 2026

Published Date: March-2021 | Number of Pages: 65 | Format: PDF | Report ID: KBV-14530

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Inhaled Nitric Oxide Market, by Application
1.4.2 Europe Inhaled Nitric Oxide Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies deployed in Inhaled Nitric Oxide Market

Chapter 4. Europe Inhaled Nitric Oxide Market by Application
4.1 Europe Neonatal Respiratory Treatment Repellent Market by Country
4.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country
4.3 Europe Acute Respiratory Distress Syndrome (ARDS) Market by Country
4.4 Europe Other Applications Market by Country

Chapter 5. Europe Inhaled Nitric Oxide Market by Country
5.1 Germany Inhaled Nitric Oxide Market
5.1.1 Germany Inhaled Nitric Oxide Market by Application
5.2 UK Inhaled Nitric Oxide Market
5.2.1 UK Inhaled Nitric Oxide Market by Application
5.3 France Inhaled Nitric Oxide Market
5.3.1 France Inhaled Nitric Oxide Market by Application
5.4 Russia Inhaled Nitric Oxide Market
5.4.1 Russia Inhaled Nitric Oxide Market by Application
5.5 Spain Inhaled Nitric Oxide Market
5.5.1 Spain Inhaled Nitric Oxide Market by Application
5.6 Italy Inhaled Nitric Oxide Market
5.6.1 Italy Inhaled Nitric Oxide Market by Application
5.7 Rest of Europe Inhaled Nitric Oxide Market
5.7.1 Rest of Europe Inhaled Nitric Oxide Market by Application

Chapter 6. Company Profiles
6.1 Getinge AB
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Merck Group
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Halma PLC
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Linde PLC (Praxair, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Acquisition and Mergers:
6.5 Air Liquide S.A.
6.5.1 Company Overview
6.5.1 Financial Analysis
6.6 Beyond Air, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expense
6.6.4 Recent strategies and developments:
6.6.4.1 Trials and Approvals:
6.7 Mallinckrodt PLC (International Minerals and Chemical Corporation)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Trials and Approvals:
6.7.5.2 Partnerships, Collaborations, and Agreements:
6.8 VERO Biotech LLC
6.8.1 Company Overview
6.8.2 Recent strategies and developments:
6.8.2.1 Trials and Approvals:
6.9 Nu-Med Plus, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, Collaborations, and Agreements:
6.10. Novoteris, LLC
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Trials and Approvals:

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities